Search results for Eculizumab

Eculizumab Biosimilar – Anti-C5 mAb – Research Grade, ProteoGenix, PX-TA1039

Description of Eculizumab Biosimilar - Anti-C5 mAb - Research Grade Eculizumab Biosimilar – Anti-C5 mAb – Research Grade Eculizumab Biosimilar – Anti-C5 mAb – Research Grade: A Revolutionary Therapeutic Antibody Targeting Complement Component 5 Introduction Eculizumab Biosimilar, also known as Anti-C5 mAb, is a research-grade monoclonal antibody that specifically targets complement component 5 (C5). This biosimilar is a groundbreaking therapeutic antibody that has shown promising results in the treatment of various complement-mediated diseases. In this article, we will delve into the structure, activity, and applications of Eculizumab Biosimilar. Structure of Eculizumab Biosimilar Eculizumab Biosimilar is a recombinant humanized monoclonal antibody that is derived from the parent antibody, Eculizumab. It is composed of two identical heavy chains and two identical light chains, each with a molecular weight of approximately 150 kDa. The antibody has a unique structure with two antigen-binding fragments (Fab) that bind to the C5 protein and a constant fragment (Fc) that mediates effector functions. Activity of Eculizumab Biosimilar Eculizumab Biosimilar exerts its therapeutic effect by specifically targeting and inhibiting the activity of C5, a key component of the complement system. The complement system is a crucial part of the immune system that helps in the defense against pathogens. However, dysregulation of the complement system can lead to various diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Eculizumab Biosimilar blocks the cleavage of C5 into C5a and C5b, preventing the formation of the membrane attack complex (MAC) and the release of pro-inflammatory mediators, thus reducing tissue damage and inflammation. Applications of Eculizumab Biosimilar Eculizumab Biosimilar has shown promising results in the treatment of various complement-mediated diseases, including PNH, aHUS, and myasthenia gravis. PNH is a rare and life-threatening hematological disorder characterized by the destruction of red blood cells, leading to anemia, fatigue, and other complications. Eculizumab Biosimilar has been approved for the treatment of PNH and has shown to improve symptoms and quality of life in patients. aHUS is a rare genetic disorder that causes abnormal blood clots in small blood vessels, leading to damage to vital organs such as the kidneys. Eculizumab Biosimilar has been approved for the treatment of aHUS and has shown to improve kidney function and reduce the risk of organ damage. Moreover, Eculizumab Biosimilar has shown promising results in the treatment of myasthenia gravis, a neuromuscular disorder characterized by muscle weakness and fatigue. Eculizumab Biosimilar has been shown to improve muscle strength and function in patients with myasthenia gravis. Conclusion In conclusion, Eculizumab Biosimilar is a revolutionary therapeutic antibody that specifically targets C5 and has shown promising results in the treatment of various complement-mediated diseases. Its unique structure and mechanism of action make it a promising option for patients who do not respond to conventional treatments. With ongoing research and development, Eculizumab Biosimilar has the potential to improve the lives of patients suffering from complement-mediated diseases.

Eculizumab, Affinityimmuno, ab-131-eculizumab

Eculizumab, Abbexa, abx831006

Eculizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting C5, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Eculizumab is a recombinant humanized monoclonal antibody against the complement protein C5.

Eculizumab Antibody, Abbexa, abx376584

Eculizumab Antibody is a rabbit polyclonal antibody for the detection of Eculizumab.

Anti-Eculizumab Polyclonal Antibody, AntibodySystem, PAB90001

Eculizumab Biosimilar - Research Grade, ichor.bio, ICH4005

Detects human Complement protein C5. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Eculizumab.

Anti-Eculizumab Neutralizing Antibody ELISA kit, ProteoGenix, KPTX300

Description of Anti-Eculizumab Neutralizing Antibody ELISA kit Structure of Anti-Eculizumab Neutralizing Antibody ELISA Kit The Anti-Eculizumab Neutralizing Antibody ELISA kit is a powerful tool used in the field of immunology to detect and quantify the presence of anti-Eculizumab neutralizing antibodies in biological samples. This kit is specifically designed to target the therapeutic antibody Eculizumab, which is used in the treatment of various autoimmune disorders. In this article, we will discuss the structure, activity, and application of the Anti-Eculizumab Neutralizing Antibody ELISA kit. Structure of the Kit The Anti-Eculizumab Neutralizing Antibody ELISA kit is composed of several components that work together to accurately detect and measure the levels of anti-Eculizumab neutralizing antibodies in a sample. The main components of the kit include a microplate coated with Eculizumab, a detection antibody labeled with an enzyme, and a substrate solution. The microplate is specifically designed to capture any anti-Eculizumab neutralizing antibodies present in the sample, while the detection antibody binds to these antibodies and produces a color change in the presence of the substrate solution. Activity of the Kit The activity of the Anti-Eculizumab Neutralizing Antibody ELISA kit is based on the principle of enzyme-linked immunosorbent assay (ELISA). This technique utilizes the specific binding of an antigen (Eculizumab) and its corresponding antibody (anti-Eculizumab neutralizing antibody) to detect and quantify the presence of the antibody in a sample. The microplate is coated with Eculizumab, which serves as the antigen, and the detection antibody is labeled with an enzyme that produces a color change in the presence of the substrate solution. The intensity of the color is directly proportional to the amount of anti-Eculizumab neutralizing antibodies present in the sample. Application of the Kit The Anti-Eculizumab Neutralizing Antibody ELISA kit has a wide range of applications in both research and clinical settings. In research, this kit is used to study the immunogenicity of Eculizumab in patients receiving treatment for autoimmune disorders. It can also be used to monitor the development of neutralizing antibodies against Eculizumab over time. In clinical settings, the kit is used to assess the effectiveness of Eculizumab treatment and to identify patients who may be at risk of developing adverse reactions to the therapy. Therapeutic Target The therapeutic target of the Anti-Eculizumab Neutralizing Antibody ELISA kit is the therapeutic antibody Eculizumab. This monoclonal antibody targets and blocks the activity of complement protein C5, which plays a crucial role in the development of certain autoimmune disorders. Eculizumab has been approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and myasthenia gravis (MG). However, in some patients, the development of anti-Eculizumab neutralizing antibodies can reduce the effectiveness of the therapy, leading to treatment failure. Research Use In research, the Anti-Eculizumab Neutralizing Antibody ELISA kit is used to study the immunogenicity of Eculizumab and to monitor the development of neutralizing antibodies in patients receiving treatment for autoimmune disorders. This information is crucial in understanding the efficacy and safety of Eculizumab and can aid in the development of new therapies for these conditions. In conclusion, the Anti-Eculizumab Neutralizing Antibody ELISA kit is a valuable tool in the field of immunology, specifically targeting the therapeutic antibody Eculizumab. Its accurate and sensitive detection of anti-Eculizumab neutralizing antibodies makes it a valuable asset in both research and clinical settings, providing crucial information for the development and monitoring of Eculizumab therapy.